Asset Details
Do you wish to reserve the book?
Cardiorenal protective effects of Tanhuo decoction in acute myocardial infarction via regulating multi-target inflammation and metabolic signaling pathways
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cardiorenal protective effects of Tanhuo decoction in acute myocardial infarction via regulating multi-target inflammation and metabolic signaling pathways
Do you wish to request the book?
Cardiorenal protective effects of Tanhuo decoction in acute myocardial infarction via regulating multi-target inflammation and metabolic signaling pathways
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Cardiorenal protective effects of Tanhuo decoction in acute myocardial infarction via regulating multi-target inflammation and metabolic signaling pathways
2025
Overview
Inflammation is a key driver of adverse outcomes in acute myocardial infarction (AMI), yet current western anti-inflammatory therapies are limited by their single-target nature and side effects. Traditional Chinese medicine (TCM), such as Tanhuo Decoction (THD), offers a multi-target, low-toxicity alternative.
In a randomized controlled trial, AMI patients with high inflammatory responses received either standard Western medicine (WM) alone or combined with THD for 3 days. Clinical outcomes and inflammatory markers were assessed, and proteomic and network pharmacology analyses were performed.
The THD + WM group showed significant reductions in neutrophil counts and hs-CRP levels, along with improved creatinine clearance rate (CCR), compared to WM alone. Proteomic analysis revealed downregulation of pro-inflammatory proteins (PTX3, IL-18, TNFRSF11A) and upregulation of the anti-inflammatory IL1RL2. THD also modulated lipid metabolism and insulin sensitivity pathways.
THD enhances the anti-inflammatory and metabolic benefits of standard AMI therapy through multi-target pathway regulation. These findings support its integration into modern cardiovascular care, particularly for patients with high inflammatory and metabolic risk.
